India Marks Breakthrough in Cancer Care: Tata Memorial Pioneers High-Dose MIBG Therapy
India Marks Breakthrough in Cancer Care: Tata Memorial Pioneers High-Dose MIBG Therapy
In a landmark development for cancer treatment in India, Mumbai’s Tata Memorial Centre has become the first hospital in the country to successfully deliver high-dose MIBG therapy — a targeted nuclear medicine technique crucial in treating neuroblastoma, a rare and aggressive childhood cancer.
The breakthrough treatment was administered on May 5, 2025, at Tata Memorial’s Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) in Navi Mumbai. A 17-year-old patient with relapsed neuroblastoma received an 800 mCi dose of radioactive Iodine-131 labelled MIBG — an amount that demands stringent safety measures and specialized infrastructure. Later, on May 29, the patient underwent an autologous stem cell transplant and is reported to be in stable condition.
How MIBG Therapy Works
MIBG (Metaiodobenzylguanidine) therapy harnesses radioactive isotopes to directly target neuroendocrine tumors, delivering high-precision radiation that destroys cancer cells while sparing most healthy tissues. Combining elements of chemotherapy, radiation, and nuclear medicine, the therapy is particularly valuable for advanced neuroblastoma cases, which often present late and resist conventional treatment.
Built on Collaboration and Cutting-Edge Technology
The high-dose procedure required months of planning, rigorous safety protocols, and approvals from the Atomic Energy Regulatory Board (AERB). A purpose-built, radiation-shielded isolation ward was set up within ACTREC. The initiative was backed by India’s Department of Atomic Energy (DAE) and Bhabha Atomic Research Centre (BARC), providing the technical expertise and regulatory support needed.
Currently, Tata Memorial is the only centre in India equipped to deliver this therapy, with internationally compliant safety protocols and a dedicated high-radiation unit. While high-dose MIBG therapy is already available in countries like the US, UK, Japan, and Germany, the cost abroad can exceed ₹75 lakh per patient. At Tata Memorial, the same treatment is being offered for a fraction of that cost — around ₹7–8 lakh — and, thanks to schemes like the Pradhan Mantri Jan Arogya Yojana and support from social welfare organizations, often at minimal or no cost to patients.
A Ray of Hope for Families
India records around 1,500–2,000 new neuroblastoma cases among children each year, most diagnosed at advanced stages. High-dose MIBG therapy not only improves survival prospects but also reduces pain and tumor burden, significantly enhancing quality of life.
Tata Memorial plans to scale up the therapy to benefit 5–6 patients each month, paving the way for wider adoption. Experts hope this success story will inspire other cancer centres across India to develop similar capabilities, especially in states and regions where advanced cancer treatment remains out of reach.
This pioneering effort stands as a testament to India’s growing expertise in complex nuclear medicine, signaling a new era where life-saving cancer therapies can be both world-class and accessible.
